AQP4 and neuromyelitis optica: To extend these findings, we applied the same methodology to a nationwide neuromyelitis optica spectrum disorder cohort (2006–2020) using Taiwan’s National Health Insurance Research Database, which does not include aquaporin 4 serostatus information; thus, the data made it impossible to distinguish seropositive from seronegative nationwide neuromyelitis optica spectrum disorder cases.